Hospital de Câncer de Barretos - Fundação PIO XII

Hospital de Câncer de Barretos - Fundação PIO XII
Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400
Select an option

Our team

Medical staff
Bruna Minniti Mancano
Arinilda Campos Bragagnoli
João Neif
Hadson Araujo
Pamela Bozzo
Mariana Campos
Flavio Carcano
Guilherme Costa.
Henrique Maia
Giovana Oliveira Del Arco
Daniel Preto
Dayana Ribeiro
Lucas Estevão Zanini
Carlos E Baston Silva

Open studies

Lung cancer
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - AbbVieSee more
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer - PALOMA-2 - Janssen Research & Development, LLCSee more
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) - Merck Sharp & Dohme LLCSee more
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations - AMIGO-1 - Latin American Cooperative Oncology GroupSee more
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.See more
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer - Krascendo 1 - Hoffmann-La RocheSee more
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) - heredERA - Hoffmann-La RocheSee more
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Head and neck cancer
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients - Vyriad, Inc.See more
NBTXR3 With or Without Cetuximab in LA-HNSCC - NanobiotixSee more
Multiple myeloma
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - EXCALIBER-RRMM - CelgeneSee more
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment - MonumenTAL-3 - Janssen Research & Development, LLCSee more
Skin cancer
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma - RELATIVITY-127 - Bristol-Myers SquibbSee more
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients - Vyriad, Inc.See more
Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy - IMvigor011 - Hoffmann-La RocheSee more
Colorectal cancer
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients - Vyriad, Inc.See more
Liver Cancer
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) - SKYSCRAPER-14 - Hoffmann-La RocheSee more
Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) - MK4280A-008 - Merck Sharp & Dohme LLCSee more
Solid tumors
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer - PALOMA-2 - Janssen Research & Development, LLCSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy